MktsMarkets

Alzamend Neuro, Inc.
NASDAQ: ALZNKey statistics
ALZN News
Stories mentioning ALZN from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Jan 31 | Q4 '25Oct 31 | Q3 '25Jul 31 | Q2 '25Apr 30 | Q1 '25Jan 31 | Q4 '24Oct 31 | Q3 '24Jul 31 | Q2 '24Apr 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | ||||||||
| Cost of Goods Sold | ||||||||
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | ||||||||
| Research & Development | 1,279 | 176.00 | 1,741 | 450.00 | 447.00 | 311.00 | 207.00 | 183.00 |
| Sales General & Admin | ||||||||
| Total Operating Expenses | 2,198 | 998.00 | 2,700 | 1,140 | 1,037 | 1,358 | 962.00 | 850.00 |
| Operating Income (Loss) | (2,198) | (998.00) | (2,700) | (1,140) | (1,037) | (1,358) | (962.00) | (850.00) |
| Interest Income | ||||||||
| Interest Expense | 1.00 | 3.00 | 2.00 | 1.00 | 2.00 | 3.00 | 12.00 | 2.00 |
| Other Expense | ||||||||
| Pretax Income | ||||||||
| Tax Provision | ||||||||
| Net Income (Loss) | (2,199) | (1,001) | (2,703) | (1,140) | (1,039) | (1,362) | (974.00) | (852.00) |
| Earnings Per Share (Basic) | (0.58) | (0.30) | (1.28) | (2.53) | (1.75) | (3.61) | (11.42) | (11.51) |
| Earnings Per Share (Diluted) | (0.58) | (0.30) | (1.28) | (2.53) | (1.75) | (3.61) | (11.42) | (11.51) |
| Weighted Average Shares Outstanding (Basic) | 3,805 | 3,381 | 2,106 | 451.00 | 612.00 | 392.00 | 85.00 | 74.00 |
| Weighted Average Shares Outstanding (Diluted) | 3,805 | 3,381 | 2,106 | 451.00 | 612.00 | 392.00 | 85.00 | 74.00 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About ALZN
Alzamend Neuro, Inc. (NASDAQ: ALZN) is a stock listed on the Nasdaq Stock Market under the ticker symbol ALZN. It last traded at $1.40 (Nov 11, 2026, 3:49 PM ET), up 3.7% on the day. That gives Alzamend Neuro a market capitalisation of $6.5M.
Over the past 52 weeks ALZN has traded between $0.8400 and $2.58.
For the quarter ended Jan 31, 2026 it reported a net loss of $2.2M.
| Quarter ended | Revenue | Net income |
|---|---|---|
| Jan 31, 2026 | — | -$2.2M |
| Oct 31, 2025 | — | -$1.0M |
| Jul 31, 2025 | — | -$2.7M |
| Apr 30, 2025 | — | -$1.1M |
From Alzamend Neuro’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…